You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Chapter title |
Adjuvant Endocrine Therapy
|
|---|---|
| Chapter number | 2 |
| Book title |
Optimizing Breast Cancer Management
|
| Published in |
Cancer treatment and research, January 2018
|
| DOI | 10.1007/978-3-319-70197-4_2 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-970195-0, 978-3-31-970197-4
|
| Authors |
Rena Shah, Ruth M. O’Regan |
| Abstract |
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects. Molecular profiling has allowed therapy to be tailored for an individual patient to some extent. However, further molecular studies are needed to individualize the choice and length of adjuvant hormone therapy. Ongoing studies are evaluating the role of additional targeted therapies, such as CDK4/6 inhibitors, to further improve outcome for patients with early-stage hormone receptor-positive breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 15% |
| Other | 2 | 10% |
| Researcher | 2 | 10% |
| Student > Ph. D. Student | 2 | 10% |
| Student > Doctoral Student | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 9 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Social Sciences | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 9 | 45% |